(*) The success rate depends on the type of cancer and the patient’s condition
One blood sample only
Detecting five common types of cancer at the same time
Accuracy of
up to 99%*
Optimal cost suitable for Vietnamese people
*Based on 2000 samples at 13 major cancer hospitals, screening for positive cases gives 99% accuracy after diagnosis.
This method is not intended to replace important routine cancer screenings
Based on circulating tumor DNA (ctDNA)
Using next-generation sequencing
Detects the presence or absence of ctDNA in the blood
Return results and advice after the test
SPOT-MASTM: Based on next-generation gene sequencing technology
April 15, 2022–July 31, 2022
Cooperating with the 14 largest cancer hospitals nationwide.
2000 screening samples.
August 8, 2022–October 31, 2022
Share screening samples with more than 50 hospitals, cancer clinics and the largest enterprises in Vietnam.
5000 screening samples.
From November 2022 to 2025
Continue to mobilise funds for cancer prevention, the General Medical Association, large hospitals and leading businesses sponsoring more screening samples in the community.
Outstanding advantages of SPOT-MASTM technology
Nằm trong chuỗi hoạt động truyền thông chương trình cộng đồng Chung tay đẩy lùi ung thư của Gene Solutions, talk tư vấn "Phát hiện sớm để đẩy lùi ung thư" được phát trực tuyến lúc 14h, ngày 21/9 trên báo điện tử VnExpress và
Copyright © 2020 GENE SOLUTIONS
Legal Representative: Nguyễn Hữu Nguyên
Enterprise No. 0314215140 – HCMC D.P.I issued on January 23, 2017
Tư vấn di truyền